Medicine
Vosevi 400 mg/100 mg/100 mg tablet
Vosevi 400 mg/100 mg/100 mg tablet is a prescription medicine containing Sofosbuvir, Velpatasvir and Voxilaprevir for oral use, marketed by Gilead Sciences, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store below 30 °C (86 °F).
Key facts
- Active ingredient (INN)
- Sofosbuvir, Velpatasvir and Voxilaprevir
- Brand
- Vosevi
- Strength
- 400 mg/100 mg/100 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 28 tablets
- Marketing authorisation holder
- Gilead Sciences
- Manufacturer
- Gilead Sciences
- Origin register
- US FDA, United States
- Storage
- Store below 30 °C (86 °F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AP56 Sofosbuvir, Velpatasvir and Voxilaprevir
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 18 July 2017
- Identifiers
- RxCUI 1939329, 1939335DailyMed set ID 17ffc094-8ca7-45d2-80d8-fd043bc9a221NDC 61958-2401Application NDA209195
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 28 tablet, film coated in 1 bottle, plastic | 61958-2401-1 | Gilead Sciences | 18 July 2017 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 18 July 2017 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Sofosbuvir, Velpatasvir and Voxilaprevir is a fixed-dose combination of a hepatitis C virus NS3/4A protease inhibitor, a hepatitis C virus NS5A inhibitor and a hepatitis C virus nucleotide analog NS5B polymerase inhibitor. MedsAcross supplies Sofosbuvir, Velpatasvir and Voxilaprevir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Sofosbuvir, Velpatasvir and VoxilaprevirFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Vosevi prescribing information (Gilead Sciences) · U.S. National Library of Medicine, DailyMed
Need Vosevi 400 mg/100 mg/100 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.